



March 3, 2022

Spring Discovery Announces Grant to Discover Novel Vaccine Adjuvants Using AI Powered Technology Platform

SAN CARLOS, California, 3/3/22 – Spring Discovery, a biotechnology company focused on discovery of therapies for age-related diseases, today announced a grant from the Bill & Melinda Gates Foundation of \$1.2 million to apply the company's proprietary AI-powered technology platform to immunophenotype existing vaccine adjuvants and use this proprietary information to discover novel vaccine adjuvants.

"Spring is excited to work with the Bill & Melinda Gates Foundation and their world-leading experts to help discover and characterize novel vaccine adjuvants", said Spring CEO Ben Kamens. "Vaccines are one of our most effective tools in the fight against disease, and using new technology to aid in the systematic discovery and understanding of adjuvants is very important."

About Vaccine Adjuvants

An adjuvant is a pharmacological or immunological agent that modifies the effect of other agents. Adjuvants are added to a vaccine to boost the immune response to produce more antibodies and longer-lasting immunity, thus minimizing the dose of antigen needed. Adjuvants may also be used to enhance the efficacy of a vaccine by helping to modify the immune response by particular types of immune system cells.

About Spring Discovery

Spring Discovery builds world-leading technology to help scientists discover and develop therapies for age-related diseases. The company's proprietary machine learning and wetlab automation platform is capable of generating high-dimensional phenotypic data that combines multiple modalities of biological readouts into single assays at unprecedented scale. This technology powers high-throughput therapeutic screens capable of measuring multiple cell behaviors while searching for therapies for multiple diseases associated with aging.

Spring Discovery's leaders and advisors are experts in machine learning, therapeutic discovery, and clinical development. The company's platform is being used for multiple programs in a wide range of diseases across both internal programs and partnerships.

Contact:

Spring Discovery, Inc
press@springdiscovery.com